• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Athos Therapeutics Taps Vultr Cloud GPU to Power AI Drug Discovery Engine

by Syed Hamza Sohail 06/19/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

–              Vultr, the world’s largest, privately-held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to run its AI model training, tuning, and inference.

–              Powered by NVIDIA HGX H100 systems and running on Dell Technologies’ PowerEdge XE9680 servers, Vultr now offers Athos the needed security and confidentiality for their intellectual property, omics* data, and proprietary AI algorithms

Vultr: Empowering Athos’ Precision Therapeutics with Secure, Scalable AI Cloud Infrastructure

Athos, led by key figures from Kite Pharma and boasting significant achievements in medicinal chemistry and drug discovery, pioneers AI and machine learning-driven small-molecule therapeutics for immune-mediated diseases and cancer. Their mission involves unraveling the complexities of autoimmune and cancer biology at the molecular level. Partnering with leading hospitals like the Cleveland Clinic and University of Ioannina Medical School, Athos conducts multi-omics analysis on over 25,000 patients. Additionally, collaborations with Caltech involve spectrometry-based proteomics using patient samples.

To expedite their precision therapeutics development, Athos required a cloud infrastructure that was both cost-effective and capable of handling vast omics data and proprietary AI algorithms. Previous experiences with public cloud providers proved costly and lacked sufficient engineering support. Consequently, Athos opted for Vultr, which provides secure access to NVIDIA GPUs for AI algorithm training. This choice ensures compliance with data sovereignty and privacy regulations, crucial for handling sensitive AI training data.

By leveraging Vultr’s platform, Athos seamlessly scales their AI analytical capabilities, including their data lake and integrative deep machine learning engine. They benefit from agile GPU resources that accommodate growing data demands and mitigate the complexities associated with managing GPUs. The user-friendly interface simplifies interactions with computational resources, accelerating algorithm training without requiring deep technical GPU expertise.

Continuous monitoring and management tools further optimize resource utilization and enhance operational efficiency. Athos also prioritizes security, ensuring unmatched confidentiality for their omics data and proprietary AI algorithms. Their partnership with Vultr guarantees 24/7 support, essential for disaster recovery and maintaining the integrity of their data and AI models in the event of hardware or software failures.

In conclusion, Vultr’s AI cloud platform empowers Athos to innovate rapidly in precision therapeutics, facilitating advanced research into immune-mediated diseases and cancer with robust, scalable, and secure cloud infrastructure.


“Enabling the next wave of innovators is core to our mission of democratizing access to high-performance cloud compute,” said Amit Rai, General Manager of AI and Enterprise Cloud, Vultr. “And for a company like Athos, which operates in a highly regulated industry, security and compliance are top considerations for maintaining operational excellence. We are proud to be working with Athos, providing the scalable, performant, safe, and secure infrastructure that will underpin their platform, as the company continues to scale and deliver life-changing therapeutics for patients around the world.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Drug Discovery

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |